Generics - Oncology

Filter

Current filters:

Oncology

Popular Filters

76 to 99 of 99 results

Bayer challenges Indian ruling on Nexavar patent

08-05-2012

German drug major Bayer (BAYN: DE) has launched an appeal against the Indian Patent Office, which a couple…

Asia-PacificBayerGenericsLegalNexavarOncologyPatentsPharmaceutical

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Cancer drugs shortages persist in Poland

26-04-2012

In Poland, the recent procurement problems of cancer drugs is far from solved, writes Sebastian Gensior…

EuropeGenericsHealthcareNovartisOncologyPharmaceuticalPricingSandoz

India issues compulsory license for Bayer cancer drug Nexavar

13-03-2012

The Indian Patent Office has issued the first-ever compulsory licence in India to a generic drug manufacturer.…

Asia-PacificBayerGenericsNatco PharmaNexavarOncologyPatentsPharmaceutical

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

Hospira progresses biosimilar Epogen

11-01-2012

USA-based Hospira (NYSE: HSP), a leading provider of generic injectable drugs and infusion technologies,…

AmgenBiotechnologyEpogenerythropoietinGenericsHospiraNephrology and HepatologyOncologyResearch

Amgen in cancer biosimilars deal with Watson

20-12-2011

A collaboration has been entered into by Amgen (Nasdaq: AMGN), the world’s largest independent biotech…

AmgenBiotechnologyGenericsGlobalLicensingMarkets & MarketingOncologyWatson Pharmaceuticals

NSCL cancer drug market set to grow 2.5% a year between 2010 and 2020, despite generic erosion

06-12-2011

Despite the arrival of generic competition – and ensuing sales erosion for several key agents used…

GenericsMarkets & MarketingOncologyPharmaceutical

Actavis to boost oncology presence in Turkey, with generic drug launches

30-11-2011

Iceland-headquartered generic drugmaker Actavis is planning to increase its presence in Turkey next year…

ActavisEuropeGenericsMarkets & MarketingOncology

Strides Arcolab gets two more cancer generics approved in USA

27-11-2011

Onco Therapies, a wholly owned subsidiary of Indian generics drugmakers Strides Arcolab (BO: 532531),…

CarboplatinGenericsMarkets & MarketingNorth AmericaOnco TherapiesOncologyOxaliplatin InjectionPfizerRegulationStrides Arcolab

AEterna Zentaris signs up Hikma to commercialize perifosine in MENA region

24-11-2011

Canada’s AEterna Zentaris (TSX: AEZ) has signed an exclusive commercialization and licensing agreement…

AEterna ZentarisGenericsHikma PharmaceuticalsLicensingOncologyperifosinePharmaceuticalRest of the World

Some 40% of G7 ESA markets to be biosimilars by 2020, and insulins to reach $1 billion, says DR report

30-10-2011

By 2020, biosimilar versions of erythropoietin stimulating agents (ESAs) will garner 40% market share…

BiotechnologyDiabetesGenericsGlobalMarkets & MarketingOncology

Mylan enters settlement and license deal with Roche over Xeloda

21-09-2011

US generic drugs giant Mylan (Nasdaq: MYL) says that it has entered into a settlement and license agreement…

GenericsLegalLicensingMylan LaboratoriesNorth AmericaOncologyRocheXeloda

Glycotope enrolls first patient for “biobetter” of Roche cancer drug Herceptin

20-09-2011

Berlin, Germany-based glycomics specialist Glycotope GmbH says it has enrolled the first patients in…

BiotechnologyGenericsGlycotopeHerceptinOncologyResearchRochetrastuzumab

Teva ups stake in CureTech to 75% following positive clinical results in lymphoma

14-09-2011

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says it is exercising its option to make an…

CureTechGenericsMergers & AcquisitionsOncologyPharmaceuticalResearchTeva Pharmaceutical Industries

Acino links with Sawai for generic cancer drug development and distribution in Japan

08-09-2011

Switzerland’s Acino Pharma AG (SIX: ACIN) and Sawai Pharmaceutical, based in Japan, have signed…

Acino PharmaAsia-PacificGenericsLicensingMarkets & MarketingOncologySawai Pharmaceutical

Rising number of alliances to drive generics cancer drugs market, says RNCOS

07-09-2011

Increasing collaborations pertaining to cancer generics drugs have intensified in the recent times, says…

GenericsMarkets & MarketingOncology

76 to 99 of 99 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top